At a glance
At a glance
Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications.
Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications.
Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications.
The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology.
The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology.
The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology.
Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease.
Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease.
Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease.
In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue regeneration indications.
In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue regeneration indications.
In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue regeneration indications.
Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes.
Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes.
Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes.
Board of Directors & Management
Board of Directors & Management
Karolis Rosickas, MS, MBA
Chief Executive Officer
Karolis Rosickas, MS, MBA
Chief Executive Officer
Karolis Rosickas, MS, MBA
Chief Executive Officer
Dr Neera Jagirdar, MD, MPH
Vice President of Clinical and Regulatory Affairs
Dr Neera Jagirdar, MD, MPH
Vice President of Clinical and Regulatory Affairs
Dr Neera Jagirdar, MD, MPH
Vice President of Clinical and Regulatory Affairs
Dr Edmund K. Waller, MD, PhD
Chairman and Chief Scientific Officer
Dr Edmund K. Waller, MD, PhD
Chairman and Chief Scientific Officer
Dr Edmund K. Waller, MD, PhD
Chairman and Chief Scientific Officer
Dr Sebastian Tseng, DDS, MBA
Non-Executive Director
Dr Sebastian Tseng, DDS, MBA
Non-Executive Director
Dr Sebastian Tseng, DDS, MBA
Non-Executive Director
Terence A. Walts, MBA
Non-Executive Director
Terence A. Walts, MBA
Non-Executive Director
Terence A. Walts, MBA
Non-Executive Director
Dr Chandra Bala
Non-Executive Director
Dr Chandra Bala
Non-Executive Director
Dr Chandra Bala
Non-Executive Director
ChiTai Chang, PhD
Non-Executive Director (Orient Euro Pharma)
ChiTai Chang, PhD
Non-Executive Director (Orient Euro Pharma)
ChiTai Chang, PhD
Non-Executive Director (Orient Euro Pharma)
Denese C. Marks, PhD
Non-Executive Director (Australian Red Cross LifeBlood)
Denese C. Marks, PhD
Non-Executive Director (Australian Red Cross LifeBlood)
Denese C. Marks, PhD
Non-Executive Director (Australian Red Cross LifeBlood)
Li-Chien Chiu
Non-Executive Director (Hocheng Corporation)
Li-Chien Chiu
Non-Executive Director (Hocheng Corporation)
Li-Chien Chiu
Non-Executive Director (Hocheng Corporation)
Corporate Governance
Corporate governance policies and charters. Cambium Bio and its Board are committed to upholding the highest standards of corporate governance in line with the ASX Corporate Governance Principles and Recommendations (3rd edition).
Careers
Careers
Join a world-class team that is passionate about developing transformational regenerative medicines to treat serious diseases.
Join a world-class team that is passionate about developing transformational regenerative medicines to treat serious diseases.
Corporate Headquarters
Cambium Bio Limited
Cambium Bio Limited
Address
16 Goodhope Street
Paddington, NSW 2021
Australia